They also analyzed the expression of EGFR, EGFR deletion mutant variant III (EGFRvIII), and phosphatase and tensin homolog (PTEN) in recurrent malignant gliomas from 26 patients receiving EGFR kinase inhibitor (EGFR-ki) therapy. Here, PTEN is linked to malignant glioma.